Although long-acting injectable (LAI) antipsychotics show benefit in the early stages of schizophrenia, they are mostly used later in the illness. This study assessed clinical and functional improvement with paliperidone LAI at different illness durations.
Research suggests a connection between the temporal lobe and frontal lobe processes, elucidating executive dysfunction in temporal lobe epilepsy. Here, read about a case of temporal lobe epilepsy with frontotemporal involvement.
People with autism spectrum disorder (ASD) experience health conditions at above-average rates, but how are they affected by concurrent mental disorders? This analysis of survey data looks at the prevalence of specific conditions such as ADHD and anxiety.
Research on suicidality in the Arab region is scarce. This study explored recent and present suicidality as well as demographic characteristics associated with such attempts among residents in this region looking for depression information online.
When you treat patients with type 1 diabetes, what clinical signs and red flags do you look for that would suggest comorbid bulimia nervosa? How should the comorbidity be treated? This narrative review summarizes the latest published evidence.
Determining whether symptoms are from a primary psychiatric disorder or secondary to another medical condition can be difficult. This report describes a patient with alcohol use disorder and mental status changes due to anti-NMDAR encephalitis.
Nonadherence to psychiatric treatment is associated with poor outcomes. This study investigated the association of socioeconomic factors, race/ethnicity, and patient perceptions with medication adherence in individuals with depression.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”